IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
IceCure Medical reported growing commercial adoption of its ProSense system in Brazil, citing increased physician interest and procedures following recent FDA marketing authorization for early-stage breast cancer. The company highlighted ongoing independent studies, including a 750-patient trial in Brazil and a planned 900-patient study in France, led by key clinical experts to evaluate cryoablation efficacy.
Key figures
- Patients brazil trial
- 750
- Patients france trial
- 900
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.